FDA to Hold Public Hearing on Psychedelic Drugs Amid White House Push

The U.S. Food and Drug Administration (FDA) is set to hold a public hearing on Monday to gather feedback on the potential therapeutic use of psychedelic drugs. The hearing represents a significant step in a push by the Trump administration to accelerate the development of these treatments for serious mental illnesses, according to a report from Reuters.

Administration Accelerates Psychedelic Research

The hearing follows a presidential order issued in April that directed the FDA to prioritize the qualification of psychedelic drug programs for its priority-voucher system. The order also instructed the agency to collaborate with the Drug Enforcement Administration (DEA) on pathways for patient access under the federal "Right to Try" law and to increase cooperation with the Department of Veterans Affairs.

Since that directive, the FDA has already issued three priority vouchers to companies developing psychedelic-based therapies. The vouchers support research into psilocybin for treatment-resistant depression and major depressive disorder, as well as methylone for post-traumatic stress disorder (PTSD).

Regulatory Framework Takes Shape

Monday's hearing will focus on the practical challenges of rolling out these novel therapies. Key topics include provider training, patient screening, long-term safety data collection, and issues of access and reimbursement. The FDA specified it is not seeking opinions on individual drug applications or the broader legalization of psychedelics.

Ad

In a sign of its proactive stance, senior FDA officials recently published a framework for psychedelic drug development in the *New England Journal of Medicine*. Jefferies analysts noted the framework suggests the agency is willing to consider flexible trial designs to address unique challenges like "functional unblinding," where a drug's noticeable psychoactive effects can compromise a study's control group. Potential solutions include using questionnaires, blinded central raters, or active comparators that mimic some of the drug's effects.

Market Implications and Industry Outlook

The administration's support has fueled renewed investor interest in the sector. Industry executives told Reuters they are hopeful for improved coordination between the FDA and DEA, which could reduce regulatory delays. Robert Barrow, CEO of Definium Therapeutics, told the newswire that regulators and industry should treat psychedelics "like it’s normal drug development."

While researchers caution that approved treatments are likely still years away, the regulatory momentum is seen as a positive signal for the industry. Analysts suggest that companies including AtaiBeckley, Compass Pathways, Definium Therapeutics, Helus Pharma, and GH Research could benefit from continued alignment between regulators and developers.